期刊文献+

癌症患者低价值医疗服务:内涵辨析、测量指标与消减策略分析

Low-value Cancer Care Services: Connotation Analysis, Measurement Indicators, and Reduction Strategy
原文传递
导出
摘要 消减低价值医疗服务是优化癌症患者服务模式、提升服务质量和价值的关键举措。文章在梳理了癌症患者低价值医疗服务的概念内涵基础上,对国内外与其相关的测量指标进行了比较,并从“个体—机构—系统”3个层面阐释了癌症患者低价值医疗服务的生成逻辑,从服务价值评估框架构建、价值评估成果传播、药物准入机制衔接、全周期医疗服务监测、赋能医患共同决策5个方面提出了癌症患者低价值医疗服务的消减策略。 Reducing low-value care is a key measure to optimize service model for cancer patients and improve the quality of and value of care. We summarizes the conceptual connotation of low-value medical services for cancer patients,compares the relevant measurement indicators at home and abroad,explains the logic of low-value medical services use for cancer patients at the three levels of“individual-institution-system”,and proposes strategies for reducing low-value medical services for cancer patients in five aspects: construction of service value framework,dissemination of evaluation results,connection of drug access mechanisms,monitoring of cancer care services,and empowering shared decision-making.
作者 李忠 张欣瑶 曹丽丽 陈鸣声 Li Zhong;Zhang Xinyao;Cao Lili(School of Health Policy and Management,Nanjing Medical University,Nanjing,210029,China;不详)
出处 《中国卫生经济》 北大核心 2024年第1期4-7,共4页 Chinese Health Economics
基金 “国家卫生健康委员会卫生技术评估重点实验室(复旦大学)”开放基金课题(FHTA2023-08) 教育部“春晖计划”合作科研项目(HZKY20220177) 教育部人才社科一般项目(23YJCZH114) 国家自然科学基金项目(71874086) 江苏省高校哲学社会科学研究基金一般项目(2022SJYB0299)。
关键词 癌症患者 低价值医疗服务 测量指标 消减策略 卫生技术评估 cancer patient low-value care measurement indicator wise choice health technology assessment
  • 相关文献

参考文献13

二级参考文献76

  • 1刘丽英,陈晶.公立医院公益性的回归[J].中国卫生经济,2015,34(3):47-49. 被引量:17
  • 2Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-indueed killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer[J]. Cancer Immunol Immunother, 2011,60(10) : 1497-1502.
  • 3Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients[J ]. Tumour Biol, 2014,35 (2) : 987-994.
  • 4Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC- activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients [J]. Cancer Immunol Immunother, 2013,62(1) :65-73.
  • 5Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer[J]. Lung Cancer, 1995,13(1) :31-44.
  • 6Kimura H1, Yamaguehi Y. A phase Ⅲ randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma [J]. Cancer, 1997,80( 1 ) : 42-49.
  • 7Yano T, Sugio K, Yamazaki K,et al. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer [J]. Lung Cancer, 1999,26(3) : 143-148.
  • 8Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma[J]. Cancer, 1996,78(2) :244-251.
  • 9Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer [J]. Anticancer Res, 2008,28(6B) :3997-4002.
  • 10Li R, Wang C, Liu L, et al. Autologous eytokine-indueed killer cell immunotherapy in lung cancer: A phase Ⅱ clinical study [J]. Cancer Immunol Immunother, 2012,61 ( 11 ) :2125-2133.

共引文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部